Artificial Intelligence and Dysplasia Detection in Inflammatory Bowel Disease (EIIDISIA Study)

INCLUSION CRITERIA:

• Adults (age ≥18 years).

• Patients with IBD meeting the following criteria:

• Diagnosis of IBD confirmed by clinical and histological evidence.

• Disease extent (Montreal classification): 1) For Ulcerative Colitis (UC), Extensivecolitis (E3): involvement proximal to the splenic flexure; or, Left-sided colitis (E2): involvement distal to the splenic flexure. 2) For Crohn's Disease (CD):Colon-only involvement (L2); or, Ileocolonic involvement (L3).

• Disease duration > 7 years.

• Patients with concommitant Primary Sclerosing Cholangitis, regardless of the extentof colonic involvement and disease duration.

• Written consent from the patient to undergo colonoscopy (signed informed consent).

EXCLUSION CRITERIA:

• Personal history of colorectal cancer (CRC).

• Previous colectomy (partial or complete).

• Coagulopathy preventing biopsy or polypectomy/mucosal resection.

• Colonoscopy performed in the last 6 months.

• Pregnant or lactating women.

• Ulcerative colitis with involvement limited to the rectum or Proctitis (MontrealE1).

• Inadequate colonic preparation due to uncleavable fecal residue during colonoscopy:Boston Bowel Preparation Scale (BBPS) = 0 or 1 in any colon segment.

• Presence of inflammatory activity due to IBD on endoscopy:1) For UC: Endoscopic MayoScore ≥ 2. 2) For CD: Simplified Endoscopic Activity Score (SES-CD) > 5.

• Incomplete lower digestive endoscopy (failure to reach the cecum).